Thermo Fisher Scientific Inc. $TMO Position Trimmed by Guinness Asset Management LTD

Guinness Asset Management LTD trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the second quarter, Holdings Channel.com reports. The firm owned 74,032 shares of the medical research company’s stock after selling 1,519 shares during the quarter. Guinness Asset Management LTD’s holdings in Thermo Fisher Scientific were worth $30,021,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth $532,360,000. EdgePoint Investment Group Inc. purchased a new position in Thermo Fisher Scientific in the first quarter valued at about $172,139,000. Cohen Investment Advisors LLC increased its position in Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock worth $167,271,000 after purchasing an additional 331,180 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. Finally, Auto Owners Insurance Co lifted its holdings in shares of Thermo Fisher Scientific by 6,773.5% during the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after buying an additional 283,810 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on TMO shares. Evercore ISI raised their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Leerink Partners raised their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Finally, JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Nineteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $595.75.

Thermo Fisher Scientific Trading Up 0.2%

Thermo Fisher Scientific stock opened at $573.07 on Monday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm has a market capitalization of $216.40 billion, a PE ratio of 33.11, a PEG ratio of 3.35 and a beta of 0.77. The business’s 50-day simple moving average is $504.04 and its 200-day simple moving average is $453.56.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the firm posted $5.28 EPS. The company’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,666 shares of company stock valued at $13,990,971. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.